New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Eli Lilly presented data at ESMO 2026 showing promising results for olomorasib, an investigational treatment for KRAS G12C-mutant non-small cell lung cancer (NSCLC). The data showed durable efficacy in combination with immunotherapy, with or without chemotherapy, across PD-L1 expression levels. Olomorasib is not yet approved but has received Breakthrough Therapy designation from the FDA. The ongoing Phase 3 SUNRAY-01 study is evaluating olomorasib in first-line KRAS G12C-mutant NSCLC.

Lilly presented data at ESMO showing olomorasib, an experimental KRAS G12C inhibitor, combined with immunotherapy demonstrated median progression-free survival of 14.5 months in advanced NSCLC. Lilly expects Phase 3 data in 2027. Olomorasib is not yet approved but has received Breakthrough Therapy designation from the FDA.

The iShares Biotechnology ETF (IBB) rose 23.1% through Oct. 23, driven by drug milestones. Merck and Moderna reported positive Phase 3 trial data for intismeran autogene. Roche's Enspryng gained FDA approval for thyroid eye disease. Eli Lilly plans to submit a weight-loss drug for FDA review in early 2027. IBB's expense ratio is 0.44%, while SPDR S&P Biotech ETF (XBI) has a 0.35% expense ratio.

Eli Lilly (NYSE: LLY) reported Phase 1 trial results for sofetabart mipitecan combined with Avastin, showing a 79% objective response rate and 100% disease control rate in platinum-sensitive ovarian cancer. The company is deemed modestly undervalued with a GF Value™ of $1,587.05, a 19.8% premium to its current price. Eli Lilly has a GF Score™ of 96/100, reflecting strong financial health and growth. No insider buying was reported in the past year, with $2.66 billion in insider sales.

Eli Lilly reported early-stage data showing high response rates for sofetabart mipitecan (Sofe-M) combined with Avastin in treating platinum-sensitive ovarian cancer. The Phase 1 trial results were shared by the company.

Eli Lilly's ovarian cancer drug Sofe-M showed a 79% response rate and 100% disease control in new data. The company is evaluating it in a Phase 3 trial with three parts. The drug's safety profile was consistent with known profiles. LLY stock is up 19% year-to-date and 55% over the past 12 months.